Device Trial Radar · NCT00853632
Magna® Mitral Pericardial Bioprostheses Post-Approval Study Protocol
Last checked: Nov 20, 2026Latest source record: May 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
329
Actual
Start
Aug 2007
Primary completion
Mar 6, 2024
Study completion Mar 6, 2024
Sponsor
- Lead sponsor
- Edwards LifesciencesPublic (EW)
- Sponsor type
- Industry
- First posted
- Mar 2, 2009
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to demonstrate the long term safety and effectiveness of the Carpentier-Edwards® PERIMOUNT Magna Mitral Valves in patients undergoing mitral valve replacement with or without concomitant procedures requiring cardiopulmonary bypass.
Conditions
- Coronary Artery Disease
- Mitral Valve Regurgitation
- Mitral Valve Incompetence
- Heart Failure
Interventions
CEP MAGNA MITRAL PERICARDIAL BIOPROSTHESESDevice
Mitral valve replacement
Primary outcomes
What the sponsor says the trial is designed to measure.
- Subject's Rate of Objective Performance Criteria Per ISO 5840-2005 - Total Number of Late Adverse Events (by Category) Divided by Late Patient Years (Expressed as a Percentage) for the Magna Mitral Valve Implanted CohortTime frame: Events occurring ≥ 31 days and up through 8 years post-implant
- Primary Effectiveness EndpointsTime frame: 8 years post-implant
Locations
15 sites in 4 countries. Site status is shown where the registry gives one.
Dignity Health Research Institute
Sacramento, California
AdventHealth Orlando
Orlando, Florida
Northwestern University Hospital
Chicago, Illinois
12 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.